Priming of hematopoietic progenitor cells by plerixafor and filgrastim in children with previous failure of mobilization with chemotherapy and/or cytokine treatment

Julián Sevilla, Elisabetta Schiavello, Luis Madero, Manuela Pardeo, Elena Guggiari, Marta Baragaño, Roberto Luksch, Maura Massimino

Research output: Contribution to journalArticlepeer-review

Abstract

Plerixafor has been recently approved by the European Medicines Agency for adult patients who have failed other mobilization strategies. Experience in children, however, is extremely limited. We describe the experience of the use of this drug in 8 children under a compassionate-use program in 3 Italian and 2 Spanish centers. Plerixafor was generally well tolerated; only 2 of 8 children reported adverse effects, and these were mild in intensity. Peripheral blood progenitor cell priming was improved with plerixafor in 6 of 8 patients. In the remaining 2 patients, the target CD34 cell count was below the target of 2×10 cells/kg, although in these patients cell counts before collection were good enough for leukapheresis. Plerixafor, therefore seems to be safe and effective for peripheral blood progenitor cell mobilization in children. Adverse events were comparable with those described with filgrastim alone.

Original languageEnglish
Pages (from-to)146-150
Number of pages5
JournalJournal of Pediatric Hematology/Oncology
Volume34
Issue number2
DOIs
Publication statusPublished - Mar 2012

Keywords

  • CD34
  • drugs
  • hematopoietic stem cells
  • leukapheresis
  • plerixafor
  • stem cell mobilization

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'Priming of hematopoietic progenitor cells by plerixafor and filgrastim in children with previous failure of mobilization with chemotherapy and/or cytokine treatment'. Together they form a unique fingerprint.

Cite this